Research programme: cancer and inflammation therapeutics - Array Biopharma/Celgene
Latest Information Update: 28 Mar 2011
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Celgene Corporation
- Class Small molecules
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer; Inflammation